Literature DB >> 526523

Predictive probability early termination plans for phase II clinical trials.

J Herson.   

Abstract

A phase II clinical trial is designed to gather data to help decide whether an experimental treatment has sufficient effectiveness to justify further study. In a one-arm trial with dichotomous outcome, we wish to test a simple null hypothesis on the Bernoulli parameter against a one-sided alternative in a sample of N patients. It is advisable to have a rule to terminate the trial early when evidence accumulates that the treatment is ineffective. Predictive probabilities based on the binomial distribution and beta and uniform prior distributions for the binomial parameter are found to be useful as the basis of group sequential designs. Size, power and average sample size for these designs are discussed. A process for the specification of an early termination plan, advice on the quantification of prior beliefs, and illustrative examples are included.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 526523

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  11 in total

1.  The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  BMJ       Date:  2020-06-17

2.  Optimal and lead-in adaptive allocation for binary outcomes: a comparison of Bayesian methodologies.

Authors:  Roy T Sabo; Ghalib Bello
Journal:  Commun Stat Theory Methods       Date:  2016-04-08       Impact factor: 0.893

3.  Funding evidence: the National Institute of Neurological Disorders and Stroke Clinical Trials Program.

Authors:  Bernard Ravina; Scott Janis; Julianna Keleti; John M Marler
Journal:  NeuroRx       Date:  2004-07

4.  A predictive probability design for phase II cancer clinical trials.

Authors:  J Jack Lee; Diane D Liu
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

5.  The futility study--Progress over the last decade.

Authors:  Bruce Levin
Journal:  Contemp Clin Trials       Date:  2015-06-26       Impact factor: 2.226

6.  The utility of Bayesian predictive probabilities for interim monitoring of clinical trials.

Authors:  Benjamin R Saville; Jason T Connor; Gregory D Ayers; JoAnn Alvarez
Journal:  Clin Trials       Date:  2014-05-28       Impact factor: 2.486

7.  Interim Monitoring for Futility in Clinical Trials with Two Co-primary Endpoints Using Prediction.

Authors:  Koko Asakura; Scott R Evans; Toshimitsu Hamasaki
Journal:  Stat Biopharm Res       Date:  2019-11-04       Impact factor: 1.452

8.  Advantages of integrated trials for performing multiple Phase II studies.

Authors:  G B Weiss; J A Hokanson
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

9.  The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  Trials       Date:  2020-06-17       Impact factor: 2.279

10.  Analysis of phase II methodologies for single-arm clinical trials with multiple endpoints in rare cancers: An example in Ewing's sarcoma.

Authors:  P Dutton; S B Love; L Billingham; A B Hassan
Journal:  Stat Methods Med Res       Date:  2016-09-01       Impact factor: 3.021

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.